Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. It has a research and clinical collaboration agreement with Magenta Therapeutics, Inc. Beam Therapeutics Inc. was founded in 2017 and is based in Cambridge, Massachusetts.

Date	Fund	Action	%
2023/09/25	ARKK	Buy	0.0036
2023/09/25	ARKG	Buy	0.0037
2023/09/22	ARKK	Buy	0.0109
2023/09/22	ARKG	Buy	0.0115
2023/09/21	ARKK	Buy	0.0133
2023/09/21	ARKG	Buy	0.0146
2023/09/19	ARKK	Buy	0.0023
2023/09/19	ARKG	Buy	0.0022
2023/09/18	ARKK	Buy	0.022
2023/09/18	ARKG	Buy	0.0213
2023/09/15	ARKK	Buy	0.0088
2023/09/15	ARKG	Buy	0.0095
2023/09/14	ARKK	Buy	0.0046
2023/09/14	ARKG	Buy	0.0045
2023/09/13	ARKK	Buy	0.0385
2023/09/13	ARKG	Buy	0.0385
2023/09/07	ARKK	Buy	0.0045
2023/09/07	ARKG	Buy	0.0047
2023/09/06	ARKK	Buy	0.0002
2023/09/06	ARKG	Buy	0.0002
2023/09/05	ARKK	Buy	0.0041
2023/09/05	ARKG	Buy	0.0041
2023/08/15	ARKG	Buy	0.0245
2023/08/14	ARKG	Buy	0.0125
2023/08/11	ARKG	Buy	0.0042
2023/08/10	ARKG	Buy	0.0368
2023/08/08	ARKG	Buy	0.0174
2023/05/08	ARKK	Buy	0.0015
2023/05/08	ARKG	Buy	0.0015
2023/05/02	ARKK	Buy	0.0102